SEATTLE, Oct. 27, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global interstitial cystitis drugs market is estimated to be valued at US$ 206.6 Million in 2021 and is expected to exhibit a CAGR of 6.6% over the forecast period (2021-2028).
Key Trends and Analysis of the Global Interstitial Cystitis drugs market
Increasing drug approvals by regulatory authorities is expected to drive the market growth. For Instance, in January 2021, Kyorin Pharmaceutical Co., Ltd. received approval from the Ministry of Health, Labour and Welfare to market the interstitial cystitis IV solution “Zymso Intravesical solution 50% in Japan. Zymso is indicated for improvement of symptoms of interstitial cystitis such as chronic pelvic pain, pressure, and discomfort associated with bladder and lower urinary tract symptoms.
Furthermore, key players operating in the global interstitial cystitis drugs market are focusing on adoption of inorganic growth strategies such as acquisition, partnership, and collaboration to increase their market presence in the global market.
For instance, on January 28, 2019, Purdue Pharma L.P. and Alivio Therapeutics (companies based in U.S. involved in the production for prescription medicines) confirmed a collaboration to advance one of Alivio's product candidates through clinical development, with Purdue having the option to collaborate on a limited number of additional compounds utilizing Alivio's inflammation-targeting technology known as ALV-107. The product is a non-opioid and anti-inflammatory medication for interstitial cystitis/bladder pain syndrome (IC/BPS).
Request for Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4488
Key Market Takeaways:
The global interstitial cystitis drugs market is expected to grow at a CAGR of 6.6% during the forecast period, owing to the advent of gene therapy for the treatment of IC. According to Interstitial Cystitis Association, in 2015, TRPV-1 targeted gene therapy was studied to treat bladder pressure and pain. The animal study demonstrated a potential therapeutic effect of TRPV-1 on bladder pressure and pain behavior.
Among Region, North America is expected to lead the segment. The prevalence of IC has fueled the interstitial cystitis drugs market in the region. For instance, it was found that in the U.S. the number of cases of mild, moderate, and severe IC were reported to be 544,452, 756,184 and 211,732 respectively in 2018, which increased to around 4-12 million IC cases in 2019.
Competitive Landscape:
Key players operating in the global interstitial cystitis drugs market are Bayer AG, Eli Lilly and Co., Johnson & Johnson, Mylan NV, Novartis AG, Perrigo Co. Plc, Pfizer Inc., Seikagaku Corp., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4488
Market Segmentation:
- Global Interstitial Cystitis Drugs market, By Drugs:
- Pentosan Polysulfate Sodium
- Dimethyl Sulfoxide
- Others
- Global Interstitial Cystitis Drugs market, By Route of Administration:
- Oral Therapy
- Intravesical Therapy
- Global Interstitial Cystitis Drugs market, By End User:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Interstitial Cystitis Drugs Market, By Region:
- North America
- By Country
- U.S.
- Canada
- By Country
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country
- North America
-
- Asia Pacific
-
-
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
-
-
- Middle East
-
-
- By Country
- GCC
- Israel
- Rest of Middle East
- By Country
-
-
- Africa
-
-
- By Country
- South Africa
- Central Africa
- North Africa
- By Country
-
Related Market Intelligence Reports:
Portable Ultrasound Bladder Scanner Market, By Product Type (3D Portable Ultrasound Bladder Scanner, 2D Portable Ultrasound Bladder Scanner), By End User (Hospitals, Diagnostic Centers, Clinics, Ambulatory Surgical Centers), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027
Overactive Bladder Therapeutics Market, by Drug Type (Anticholinergics drugs { Oxybutynin, Darifenacin, Fesoterodine, Solifenacin, Tolterodine, and Trospium}, Mirabegron, and Botox), by Route of Administration (Topical, Oral, and Intravenous) by Disease (Idiopathic Bladder Overactivity, and Neurogenic Bladder Overactivity), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2021- 2028
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
